Evercore Wealth Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,494 shares of the biopharmaceutical company’s stock after buying an additional 145 shares during the quarter. Evercore Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $707,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Cigna Investments Inc. New boosted its stake in shares of Regeneron Pharmaceuticals by 0.6% in the first quarter. Cigna Investments Inc. New now owns 3,747 shares of the biopharmaceutical company’s stock valued at $1,773,000 after buying an additional 21 shares in the last quarter. First Horizon Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.4% during the 1st quarter. First Horizon Advisors Inc. now owns 500 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 21 shares during the period. Graypoint LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.3% during the 1st quarter. Graypoint LLC now owns 687 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 22 shares during the period. Zions Bancorporation N.A. increased its holdings in shares of Regeneron Pharmaceuticals by 66.7% in the 1st quarter. Zions Bancorporation N.A. now owns 55 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Finally, Ritholtz Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 3.8% during the first quarter. Ritholtz Wealth Management now owns 633 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 23 shares during the period. 82.90% of the stock is currently owned by institutional investors.
In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, June 14th. The stock was sold at an average price of $524.76, for a total value of $52,476.00. Following the completion of the sale, the director now directly owns 23,673 shares of the company’s stock, valued at $12,422,643.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Friday, May 7th. The shares were sold at an average price of $495.63, for a total value of $495,630.00. Following the completion of the sale, the executive vice president now directly owns 18,038 shares of the company’s stock, valued at $8,940,173.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,682 shares of company stock worth $46,831,512. Corporate insiders own 11.84% of the company’s stock.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 6th. The biopharmaceutical company reported $9.89 EPS for the quarter, topping analysts’ consensus estimates of $7.78 by $2.11. Regeneron Pharmaceuticals had a return on equity of 35.43% and a net margin of 43.53%. The firm had revenue of $2.53 billion for the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter in the prior year, the company posted $6.60 earnings per share. The firm’s revenue was up 38.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 46.87 earnings per share for the current year.
A number of research analysts have recently commented on REGN shares. HC Wainwright assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 29th. They set a “buy” rating and a $703.00 price objective for the company. SVB Leerink decreased their target price on Regeneron Pharmaceuticals from $657.00 to $641.00 and set an “outperform” rating for the company in a research report on Friday, May 7th. Benchmark increased their target price on Regeneron Pharmaceuticals from $590.00 to $636.00 and gave the company a “buy” rating in a research note on Thursday, July 8th. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $477.00 to $495.00 and gave the company an “equal weight” rating in a report on Friday, May 7th. Finally, Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Buy” and an average target price of $653.47.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: 12b-1 Fees
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.